Moderna mRNA Flu Vaccine 26.6% Superior in Phase 3 Trial

A Phase 3 clinical trial published in the New England Journal of Medicine has shown that Moderna's experimental trivalent mRNA influenza vaccine, mRNA-1010, reduced PCR-confirmed influenza-like illness by 26.6 percent relative to standard-dose flu vaccines among more than 40,000 adults aged 50 and o